Skip to Content

A First-of-a-Kind Gene Therapy Cure Has Struggled to Find a Market

GlaxoSmithKline’s drug Strimvelis is for sale, a sign of how hard it is to commercialize the future of medicine.

The first gene therapy to offer an out-and-out cure for any disease is for sale by its owner.

In an earnings statement released today, GlaxoSmithKline disclosed that it’s looking to sell-off its Rare Disease Unit, which made history last year by winning approval in Europe for Strimvelis, a gene-therapy to treat immune deficiency.

The treatment was just the second gene therapy to treat an inherited disease to ever reach the market, and the first to clearly and completely heal patients.

GSK’s decision to offload Strimvelis, as well as two other experimental gene therapies that have not yet been approved, highlights how challenging it has been to market complex, ultra-costly genetic treatments designed to help tiny groups of patients.  

“While we have been heavily invested in this area, we believe there is someone else who can best ensure the commercial availability of these medicines for patients,” GSK spokesperson Mary Anne Rhyne said in a statement.

Strimvelis is a gene fix that involves modifying child’s bone marrow with a corrective gene. The immune ailment, referred to as ADA-SCID, is present at birth and makes kids susceptible to fatal infections.

The treatment was notable not just for its price tag of $665,000, making it among the world’s most costly medicines, but because GSK agreed to a money-back-guarantee if patients weren’t cured, a first for gene therapy.

Although GSK never thought the drug would be a blockbuster, it appeared to fall short even of modest commercial expectations. As of May, and nearly a year after its approval, GSK had sold the treatment only once. GSK said another patient had been treated since then.

One factor limiting GSK’s sales is that some parents, instead of seeking out its drug, opted to enroll their children studies of newer gene therapies, which are being provided for free as part of clinical trials (see “10 Breakthrough Technologies: Gene Therapy 2.0”). 

“It was a first generation product,” Alex Pasteur, an investor with F-Prime Capital Partners and interim CEO of Orchard Therapeutics, which is sponsoring the newer studies, says of Strimvelis. “So I don’t think it’s a negative message for the field or this medical modality at all.”

Pasteur also says revenues for a rare-disease gene therapy might only ever add up to $100 million a year. Because GSK brings in $36 billion a year, Pasteur is not surprised the company is looking elsewhere for revenue. “These are pimples on the back of a whale,” he says. “But the assets could be very interesting for someone else.”

The decision to sell off its rare disease program affects two additional gene-therapies GSK had in development, including one for a terrifying childhood ailment called metachromatic leukodystrophy.

The only other approved gene therapy, Glybera, was pulled from the market this April after sales disappointed its maker, UniQure.

Keep Reading

Most Popular

Geoffrey Hinton tells us why he’s now scared of the tech he helped build

“I have suddenly switched my views on whether these things are going to be more intelligent than us.”

Deep learning pioneer Geoffrey Hinton has quit Google

Hinton will be speaking at EmTech Digital on Wednesday.

Video: Geoffrey Hinton talks about the “existential threat” of AI

Watch Hinton speak with Will Douglas Heaven, MIT Technology Review’s senior editor for AI, at EmTech Digital.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.